Ruxolitinib idiki molecule Janus kinase inhibitor iyo inoshandiswa mukurapa kwepakati kana yakanyanya njodzi myelofibrosis uye inodzivirira mafomu e polycythemia vera uye graft-vs-host chirwere.Ruxolitinib inosanganiswa nekukwira kwenguva pfupi uye kazhinji kunyoro mu serum aminotransferase panguva yekurapa uye kune zvisingawanzo zviitiko zvekuzvimiririra, zvinoratidzika sekiriniki idiosyncratic acute chiropa kukuvara pamwe chete nezviitiko zvekugadzirisazve hepatitis B muvanhu vanobatwa.

Ruxolitinib is an orally bioavailable Janus-associated kinase (JAK) inhibitor ine zvinogona antineoplastic uye immunomodulating zviitiko.Ruxolitinib inonyanya kusunga uye inhibits proteintyrosinekinases JAK 1 uye 2, iyo inogona kutungamirira kukudzikisira kwekuputika uye kudziviswa kwekuwedzera kwemasero.Iyo JAK-STAT (signal transducer uye activator of transcription) nzira inoita basa rinokosha pakuratidza ma cytokines akawanda uye kukura kwezvinhu uye inobatanidzwa mukupararira kwemasero, kukura, hematopoiesis, uye maitiro ekudzivirira zvirwere;JAK kinases inogona kukwidziridzwa muzvirwere zvinoputika, myeloproliferative disorders, uye zvirwere zvakasiyana-siyana.

Ruxolitinib is apyrazoleinotsiviwa panzvimbo 1 neboka re2-cyano-1-cyclopentylethyl uye panzvimbo 3 neboka repyrrolo [2,3-d] pyrimidin-4-yl.Inoshandiswa semunyu wephosphate pakurapa varwere vane myelofibrosis yepakati kana yepamusoro, kusanganisira primary myelofibrosis, post-polycythemia vera myelofibrosis uye post-essential thrombocythemia myelofibrosis.Iine basa seantineoplastic agent uye EC 2.7.10.2 (isina-specific protein-tyrosinekinase) inhibitor.Ndiyo nitrile, apyrrolopyrimidineuye nhengo yepyrazoles.